PMID- 29069718
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230809
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 42
DP  - 2017 Sep 22
TI  - Androgen receptor amplification is concordant between circulating tumor cells and 
      biopsies from men undergoing treatment for metastatic castration resistant 
      prostate cancer.
PG  - 71447-71455
LID - 10.18632/oncotarget.16169 [doi]
AB  - Increased AR activity has been shown to be preserved in spatially distinct 
      metastatic tumors from the same patient suggesting the requirement for 
      lineage-specific dependencies for metastatic castration resistant prostate cancer 
      (mCRPC). Amplification of the AR gene is a common mechanism by which mCRPC 
      increase AR activity. To determine whether AR amplification in circulating tumor 
      cells (CTC) could complement metastatic tissue biopsies in men undergoing 
      treatment for mCRPC, we developed a novel two-step assay to isolate CTCs and 
      subsequently analyzed AR amplification status in CTCs and matched biopsy tissue 
      from the same patient by fluorescence in situ hybridization (FISH). AR gene 
      status in CTCs showed strong concordance with AR gene status in matched tissue 
      samples in 24 of 25 patients (Correlation: 96%; Kappa: 0.83; Sensitivity: 100%, 
      Specificity: 83%). Our work demonstrates that AR amplification is conserved 
      between CTCs and biopsies and that CTCs can serve as non-invasive surrogate to 
      document AR amplification in mCRPC.
FAU - Podolak, Jennifer
AU  - Podolak J
AD  - Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
FAU - Eilers, Kristi
AU  - Eilers K
AD  - Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
FAU - Newby, Timothy
AU  - Newby T
AD  - Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
FAU - Slottke, Rachel
AU  - Slottke R
AD  - Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
FAU - Tucker, Erin
AU  - Tucker E
AD  - Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
FAU - Olson, Susan B
AU  - Olson SB
AD  - Department of Pathology and Laboratory Medicine, Oregon Health and Science 
      University, Portland, OR, USA.
FAU - Lue, Hui-Wen
AU  - Lue HW
AD  - Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
FAU - Youngren, Jack
AU  - Youngren J
AD  - School of Medicine, University of California, San Francisco, CA, USA.
FAU - Aggarwal, Rahul
AU  - Aggarwal R
AD  - School of Medicine, University of California, San Francisco, CA, USA.
FAU - Small, Eric J
AU  - Small EJ
AD  - School of Medicine, University of California, San Francisco, CA, USA.
FAU - Graff, Julie N
AU  - Graff JN
AD  - Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
FAU - Alumkal, Joshi J
AU  - Alumkal JJ
AD  - Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
FAU - Beer, Tomasz M
AU  - Beer TM
AD  - Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
FAU - Thomas, George V
AU  - Thomas GV
AD  - Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
AD  - Department of Pathology and Laboratory Medicine, Oregon Health and Science 
      University, Portland, OR, USA.
LA  - eng
GR  - P30 CA069533/CA/NCI NIH HHS/United States
GR  - P50 CA097186/CA/NCI NIH HHS/United States
GR  - R01 CA169172/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170313
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5641061
OTO - NOTNLM
OT  - androgen receptor
OT  - circulating tumor cells
OT  - metastases
OT  - metastatic castration resistant prostate cancer
OT  - prostate cancer
COIS- CONFLICTS OF INTEREST The authors declare that they have no competing interest
EDAT- 2017/10/27 06:00
MHDA- 2017/10/27 06:01
PMCR- 2017/09/22
CRDT- 2017/10/27 06:00
PHST- 2016/09/30 00:00 [received]
PHST- 2017/02/27 00:00 [accepted]
PHST- 2017/10/27 06:00 [entrez]
PHST- 2017/10/27 06:00 [pubmed]
PHST- 2017/10/27 06:01 [medline]
PHST- 2017/09/22 00:00 [pmc-release]
AID - 16169 [pii]
AID - 10.18632/oncotarget.16169 [doi]
PST - epublish
SO  - Oncotarget. 2017 Mar 13;8(42):71447-71455. doi: 10.18632/oncotarget.16169. 
      eCollection 2017 Sep 22.